Search results for "score"

showing 10 items of 852 documents

0057 : Preoperative Growth Differentiation Factor 15 (GDF15) as a novel biomarker of acute kidney injury after cardiac bypass surgery

2015

ObjectivePreviously, we demonstrated that preoperative plasma GDF15 levels significantly improved the prognostic value of the EuroSCORE for mortality after cardiac surgery. Despite the strong correlation between GDF15 and renal function, no data are available regarding the potential interest of preoperative GDF15 levels to improve the prediction of acute kidney injury (AKI) after coronary artery bypass grafting (CABG).Design134 patients operated on for CABG of whom 50 underwent offpump surgery at our university hospital were included in this prospective, observational study. Exclusion criteria were age 80 years, previous atrial fibrillation/flutter, previous severe renal failure (estimated …

medicine.medical_specialtyCreatininebusiness.industryAcute kidney injuryRenal functionAtrial fibrillationEuroSCOREmedicine.diseaselaw.inventionCardiac surgerychemistry.chemical_compoundchemistryBypass surgerylawInternal medicineCardiopulmonary bypassmedicineCardiologyCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Handgrip Strength Cannot Be Assumed a Proxy for Overall Muscle Strength

2018

OBJECTIVES: Dynapenia, low muscle strength, is predictive for negative health outcomes and is usually expressed as handgrip strength (HGS). Whether HGS can be a proxy for overall muscle strength and whether this depends on age and health status is controversial. This study assessed the agreement between HGS and knee extension strength (KES) in populations differing in age and health status.DESIGN: Data were retrieved from 5 cohorts.SETTING AND PARTICIPANTS: Community, geriatric outpatient clinics, and a hospital. Five cohorts (960 individuals, 49.8% male) encompassing healthy young and older individuals, geriatric outpatients, and older individuals post hip fracture were included.MEASURES: …

medicine.medical_specialtyCross-sectional studyIntraclass correlationgeriatric assessment[SDV]Life Sciences [q-bio]PopulationStandard score03 medical and health sciences0302 clinical medicineHand strengthmedicineOutpatient clinic030212 general & internal medicineeducationNursing (all)2901 Nursing (miscellaneous)General NursingHip fractureeducation.field_of_studybusiness.industryMuscle strengthHealth Policymittausta3141General Medicineknee extension strengthmedicine.diseaseaged; geriatric assessment; knee extension strength; Muscle strength; Nursing (all)2901 Nursing (miscellaneous); Health Policy; Geriatrics and GerontologyagedCohortSDG 1 - No PovertyPhysical therapyGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryikääntyneet/dk/atira/pure/sustainabledevelopmentgoals/no_povertylihasvoima
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

0058 : Low circulating levels of Growth Differentiation Factor 15 (GDF-15) before coronary artery bypass surgery may predict post-operative atrial fi…

2015

BackgroundPost-operative atrial fibrillation (POAF) following cardiac surgery has a high prevalence and is associated with considerable morbidity.AimsTo assess the role of GDF-15, a member of the TGFβsuperfamily, as a potential new predictor of POAF after off-pump (OFP) and on-pump (ONP) coronary artery bypass graft (CABG) surgery.MethodsThis observational study recruited the first 50 patients planned for OFP surgery and the first 50 patients planned for ONP surgery. Patients referred for CABG with the following exclusion criteria: age 80 years, previous atrial fibrillation/flutter, previous treatment with Amiodarone, previous cardiac surgery, emergency surgery. Included patients were equip…

medicine.medical_specialtyEjection fractionbusiness.industryAtrial fibrillationEuroSCOREAmiodaronemedicine.diseaseCardiac surgeryCoronary artery bypass surgerymedicine.anatomical_structureInternal medicineCardiologymedicinecardiovascular diseasesGDF15businessCardiology and Cardiovascular Medicinemedicine.drugArteryArchives of Cardiovascular Diseases Supplements
researchProduct

Accuracy of pre-hospital triage tools for major trauma: a systematic review with meta-analysis and net clinical benefit

2021

Abstract Background We conducted a systematic review to evaluate and compare the accuracy of pre-hospital triage tools for major trauma in the context of the development of the Italian National Institute of Health guidelines on major trauma integrated management. Methods PubMed, Embase, and CENTRAL were searched up to November 2019 for studies investigating pre-hospital triage tools. The ROC (receiver operating characteristics) curve and net clinical benefit for all selected triage tools were performed. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies–2. Certainty of the evidence was judged with the Grading of Recommendations Assessment, Developme…

medicine.medical_specialtyEmergency Medical ServicesRD1-811Major traumaContext (language use)ReviewPre-hospital Accuracy03 medical and health sciences0302 clinical medicinenursingMedicineHumans030212 general & internal medicineReceiver operating characteristicbusiness.industryRC86-88.9Major traumapre-hospital030208 emergency & critical care medicineMedical emergencies. Critical care. Intensive care. First aidmedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheTriageSample size determinationMeta-analysisEmergency medicineEmergency MedicineSystematic reviewInjury Severity ScoreWounds and InjuriesObservational studySurgeryTriagebusiness
researchProduct

Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program

2020

Diabetes is associated with a substantially increased risk of all-cause death, mainly driven by cardiovascular (CV) mortality. Furthermore, diabetes is associated with poorer outcomes after acute myocardial infarction (AMI) (1). Impaired glomerular filtration rate (GFR) is also associated with an increased risk of CV mortality (2). However, whether diabetes still confers a higher risk of mortality in patients with impaired GFR remains unknown. The aim of this study was to assess the long-term prognostic significance of both diabetes and renal impairment in two prospective nationwide cohorts of AMI patients: FAST-MI (French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarc…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Renal function030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIntensive careInternal MedicinemedicineRisk of mortality030212 general & internal medicineMyocardial infarction10. No inequalityComputingMilieux_MISCELLANEOUSAdvanced and Specialized NursingFramingham Risk Scorebusiness.industrymedicine.disease3. Good healthHeart failureCardiologybusinessKidney disease
researchProduct

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month…

2017

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time. RESULTS: Altho…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineInternal MedicinemedicineGlycemicFramingham Risk Scorebusiness.industryLiraglutideBrief ReportInsulinDiabetesLiraglutideCardiovascular riskmedicine.diseaseliraglutide diabetesMetforminEndocrinologyBlood pressureVisceral adipositybusinessmedicine.drug
researchProduct

Differences in cardiac structure and function between black and white patients: Another step in the evaluation of cardiovascular risk in chronic kidn…

2017

medicine.medical_specialtyEuropean Continental Ancestry Group030232 urology & nephrologyMEDLINE030204 cardiovascular system & hematologyLeft ventricular hypertrophyWhite PeopleCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCardiovascular DiseaseInternal MedicinemedicineHumansCardiac structureRenal Insufficiency ChronicFramingham Risk ScoreWhite (horse)business.industryRisk Factormedicine.diseaseCardiovascular DiseasesCardiologyOriginal ArticleCohort StudiebusinessCohort studyKidney diseaseHuman
researchProduct

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patient…

2018

Introduction The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data are needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with a thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus a durable coating everolimus-eluting stent (DP-EES). Material and methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX, Balton, Poland, n = 886) or DP-EES (XIENCE, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity sco…

medicine.medical_specialtyEverolimus eluting stentmedicine.medical_treatmentacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrylcsh:Rdrug-eluting stentsStentPercutaneous coronary interventionequipment and suppliesmedicine.diseaseBiodegradable polymerSurgerybioabsorbable polymerSirolimusPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugAdvances in Interventional Cardiology
researchProduct

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct